Slide 1: CHAPTER-1 Phase 2 Top-line Data
December 6, 2023 CHAPTER-1 Phase 2 Top-line Data Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This presentation includes data for an investigational product not yet approved by regulatory authorities. This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements con
Slide 3: Agenda
Agenda This presentation includes data for an investigational product not yet approved by regulatory authorities. Introduction Berndt Modig, CEO Pharvaris Review of CHAPTER-1 top-line Phase 2 data Peng Lu, M.D. PhD, CMO Pharvaris KOL perspective Marc A. Riedl, M.D., M.S., Professor of Medicine, Clin
Slide 4: Agenda
Agenda This presentation includes data for an investigational product not yet approved by regulatory authorities. Introduction Berndt Modig, CEO Pharvaris Review of CHAPTER-1 top-line Phase 2 data Peng Lu, M.D. PhD, CMO Pharvaris KOL perspective Marc A. Riedl, M.D., M.S., Professor of Medicine, Clin
Slide 5: An effective oral bradykinin B2 receptor antagonist has the potential to deliver on patient hopes
Injectable-like efficacy Easy, painless administration People living with HAE are seeking highly effective, well-tolerated and less burdensome prophylactic therapies Proprietary Pharvaris research, 2022 (representative sample of patients, n = 103, and doctors, n = 100) This presentation includes dat
Slide 6: Agenda
Agenda This presentation includes data for an investigational product not yet approved by regulatory authorities. Introduction Berndt Modig, CEO Pharvaris Review of CHAPTER-1 top-line Phase 2 data Peng Lu, M.D. PhD, CMO Pharvaris KOL perspective Marc A. Riedl, M.D., M.S., Professor of Medicine, Clin
Slide 7: CHAPTER-1, a Phase 2 prophylactic study of deucrictibant in HAE
CHAPTER-1, a Phase 2 prophylactic study of deucrictibant in HAE 92.3% reduction in occurrence of moderate and severe attacks* 92.6% reduction in occurrence of attacks treated with on-demand medication* Clinically meaningful results across primary, secondary, and health-related quality of life endpoi
Slide 8: CHAPTER-1 study design
CHAPTER-1 study design This presentation includes data for an investigational product not yet approved by regulatory authorities. Double-blind, placebo-controlled Phase 2 study evaluating deucrictibant for long-term prophylaxis in HAE-1/2 34 participants enrolled in North America and Europe R = ran
Slide 9: Participant disposition
Participant disposition 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily; 40 mg/day = deucrictibant IR capsules 20 mg twice daily; n = number of participants. This presentation includes data for an investigational product not yet approved by regulatory authorities. All Scr
Slide 10: Balanced demographics and baseline characteristics
Balanced demographics and baseline characteristics 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily. 40 mg/day = deucrictibant IR capsules 20 mg twice daily. N = number of randomized participants. This presentation includes data for an investigational product not yet appro
Slide 11: Primary endpoint met: deucrictibant significantly reduced attack rate
Primary endpoint met: deucrictibant significantly reduced attack rate This presentation includes data for an investigational product not yet approved by regulatory authorities. Monthly attack rate measured as time-normalized number of investigator confirmed HAE attacks Placebo N=11 20 mg/day N=11 40
Slide 12: Significant attack reduction and no severe attacks with deucrictibant
Significant attack reduction and no severe attacks with deucrictibant This presentation includes data for an investigational product not yet approved by regulatory authorities. Participants grouped by treatment Time (week) 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily.
Slide 13: 92.3% reduction in moderate or severe attacks at 40 mg/day dose
92.3% reduction in moderate or severe attacks at 40 mg/day dose This presentation includes data for an investigational product not yet approved by regulatory authorities. Placebo N=11 20 mg/day N=11 40 mg/day N=12 Monthly attack rate of moderate or severe attacks LS mean 1.50 0.26 0.12 % reduction v
Slide 14: 92.6% reduction in attacks treated with ODT at 40 mg/day dose
92.6% reduction in attacks treated with ODT at 40 mg/day dose This presentation includes data for an investigational product not yet approved by regulatory authorities. Placebo N=11 20 mg/day N=11 40 mg/day N=12 Monthly attack rate of attacks treated with ODT LS mean 1.41 0.35 0.10 % reduction vs pl
Slide 15: Substantial reduction of attack rate from baseline
Substantial reduction of attack rate from baseline This presentation includes data for an investigational product not yet approved by regulatory authorities. 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily. 40 mg/day = deucrictibant IR capsules 20 mg twice daily. N = numb
Slide 16: Consistent efficacy regardless of baseline attack rate
Consistent efficacy regardless of baseline attack rate This presentation includes data for an investigational product not yet approved by regulatory authorities. 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily. 40 mg/day = deucrictibant IR capsules 20 mg twice daily. N =
Slide 17: All 40 mg/day participants reported an improvement in PGA-Change
All 40 mg/day participants reported an improvement in PGA-Change This presentation includes data for an investigational product not yet approved by regulatory authorities. 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily. 40 mg/day = deucrictibant IR capsules 20 mg twice d
Slide 18: AE-QoL: improvement in health-related quality of life
AE-QoL: improvement in health-related quality of life This presentation includes data for an investigational product not yet approved by regulatory authorities. AE-QoL Total Score Placebo 20 mg/day 40 mg/day Baseline N 11 10 12 Mean 45.3 39.1 41.1 Median (Q1, Q3) 42.6 (29.4, 57.4) 37.5 (16.2, 55.9)
Slide 19: Deucrictibant well-tolerated at both doses
Deucrictibant well-tolerated at both doses This presentation includes data for an investigational product not yet approved by regulatory authorities. Placebo (N=11) 20 mg/day (N=11) 40 mg/day (N=12) Subjects n (%) Number of events Subjects n (%) Number of events Subjects n (%) Number of events TEAEs
Slide 20: All treatment-related adverse events were mild
All treatment-related adverse events were mild This presentation includes data for an investigational product not yet approved by regulatory authorities. System Organ Class Preferred Term Placebo (N=11) 20 mg/day (N=11) 40 mg/day (N=12) Participants with at least one treatment-related TEAE 1 (9.1%)
Slide 21: Main efficacy results
Main efficacy results 20 mg/day = deucrictibant immediate release (IR) capsules 10 mg twice daily; 40 mg/day = deucrictibant IR capsules 20 mg twice daily. N = number of randomized participants. LS mean = least squares mean. CI = confidence interval. *Results of monthly attack rates are based on Poi
Slide 22: Agenda
Agenda This presentation includes data for an investigational product not yet approved by regulatory authorities. Introduction Berndt Modig, CEO Pharvaris Review of CHAPTER-1 top-line Phase 2 data Peng Lu, M.D. PhD, CMO Pharvaris KOL perspective Marc A. Riedl, M.D., M.S., Professor of Medicine, Clin
Slide 23: Agenda
Agenda This presentation includes data for an investigational product not yet approved by regulatory authorities. Introduction Berndt Modig, CEO Pharvaris Review of CHAPTER-1 top-line Phase 2 data Peng Lu, M.D. PhD, CMO Pharvaris KOL perspective Marc A. Riedl, M.D., M.S., Professor of Medicine, Clin
Slide 24: Managing HAE with two oral products utilizing the same active ingredient
Managing HAE with two oral products utilizing the same active ingredient for on-demand and prophylactic treatment *Aspirational; to be confirmed with clinical data This presentation includes data for an investigational product not yet approved by regulatory authorities. Based on the results in RAPID
Slide 25: Pharvaris
PHARVARiS www.pharvaris.com ©2023